ライフサイエンスコーパス: procoagulant

1 are small membrane vesicles that are highly procoagulant.

2 ured endothelial cells rendering them highly procoagulant.

3 of cells and sheds microparticles, which are procoagulant.

4 ansformation platelets undergo when becoming procoagulant.

5 clotting times, it appeared to exert all its procoagulant actions upstream of thrombin.

6 factors to phosphatidylserine (PS)-exposing procoagulant-activated platelets followed by formation o

7 in both TUNEL(+) endothelial cell death and procoagulant activation (increased expression of both ti

8 endothelial cell death, diffuse endothelial procoagulant activation with high expression of tissue f

9 tion of anticoagulant and down-regulation of procoagulant activities in response to the local environ

10 lood flow, and increases platelet counts and procoagulant activities.

11 MP-TF assays revealed high procoagulant activity (9.05 +/- 8.82 versus 0.24 +/- 0.1

12 examined the effect of platelet clearance on procoagulant activity (PCA) in sepsis.

13 We found that ATG activated tissue factor procoagulant activity (TF PCA) on monocytic cells more p

14 s) to determine their ability to block polyP procoagulant activity and also to determine their utilit

15 ontribute to disease progression through its procoagulant activity and its capacity to induce intrace

16 ne 209 (Cys186-Cys209) bond formation for TF procoagulant activity and its de-encryption.

17 +)-dependent phosphatidylserine exposure and procoagulant activity and lack a Ca(2+)-activated cation

18 edback loop, mediating a subsequent surge in procoagulant activity and microvesicle release.

19 P2rx7) induced activation (decryption) of TF procoagulant activity and promoted release of TF+ MPs fr

20 generates new evidence implicating increased procoagulant activity and thrombin generation in the dem

21 An enhancement of platelet procoagulant activity appears to be an additional and (a

22 (C209S), or TF(C186S/C209S) expressed little procoagulant activity at the cell surface.

23 Factor Xa has procoagulant activity by conversion of prothrombin to th

24 sP-selectin enhances procoagulant activity by inducing leukocyte-derived micr

25 lation by inhibiting FXI activation or FXIIa procoagulant activity during sepsis may therefore limit

26 prethrombin-2 pathway serves to optimize the procoagulant activity expressed by activated platelets,

27 phatidylserine externalization, and platelet procoagulant activity in a CypD-dependent manner.

28 dy reduced the increased prostasome-mediated procoagulant activity in patient plasma.

29 Increased tissue factor (TF)-dependent procoagulant activity in sepsis may be partly due to dec

30 eral UHRA compounds strongly inhibited polyP procoagulant activity in vitro, and 4 were selected for

31 ion, but had minimal impact on tissue factor procoagulant activity in vitro, were conjugated with the

32 pJ mice bind to various antigens and exhibit procoagulant activity in vitro.

33 Procoagulant activity is destroyed by phospholipase C tr

34 The enhanced procoagulant activity is fully retained in plasma unless

35 Importantly, procoagulant activity is increased by the presence of an

36 Excess procoagulant activity is linked with pathological thromb

37 blockade by antibody or shRNA diminished the procoagulant activity of EMT-positive cells, confirming

38 hesis that formation of thrombin through the procoagulant activity of FVIII is necessary to induce co

39 t activation and is responsible for the full procoagulant activity of FXII.

40 phate nanoparticles mechanistically link the procoagulant activity of platelets with the activation o

41 Polyphosphate content correlated with the procoagulant activity of prostasomes.

42 also compare their effectiveness against the procoagulant activity of RNA.

43 ent of vascular thrombosis and increased the procoagulant activity of tissue factor in the liver.

44 ing thrombus formation result from increased procoagulant activity of vascular endothelial cells and

45 king increases availability of TF-FVIIa with procoagulant activity on the cell surface, while inhibit

46 ti-GRP78 AutoAbs increase tissue factor (TF) procoagulant activity on the surface of tumor cells, the

47 ion assay, they displayed significantly more procoagulant activity than particles derived from cells

48 Procoagulant activity was assessed by a functional MP-ti

49 Prostate cancer-mediated procoagulant activity was reduced in plasma in the absen

50 mbin (Trp215Ala/Glu217Ala) with less than 1% procoagulant activity was used as a relatively selective

51 flammatory mediators stimulate tissue factor procoagulant activity within atheroma to initiate a posi

52 associated with phosphatidylserine exposure (procoagulant activity), and this too was blocked in GPVI

53 ciated with increased TF protein expression, procoagulant activity, and accelerated formation of clot

54 cretion, reduces injury-induced elevation in procoagulant activity, and does not effect platelet prod

55 secondary structure may be important to its procoagulant activity, and that nucleic acids versus pol

56 in activation, granule release, aggregation, procoagulant activity, and thrombin generation in respon

57 accelerated thrombus formation and enhanced procoagulant activity, assembling a prothrombotic phenot

58 ther mAb, designated group B, inhibits fVIII procoagulant activity, fVIII binding to VWF and phosphol

59 though fibrin structure depended on cellular procoagulant activity, it did not reflect interactions b

60 g affinities for fVIII, weakly inhibit fVIII procoagulant activity, poorly inhibit fVIII binding to p

61 ty of fVIII potentially is a function of its procoagulant activity, which may result in danger signal

62 ta3 activation, alpha-granule secretion, and procoagulant activity.

63 generation of factor Va (fVa) are vital for procoagulant activity.

64 the transcription of TF and consequently its procoagulant activity.

65 s, and on microparticles (MPs) with variable procoagulant activity.

66 ies have shown that polyphosphate has potent procoagulant activity.

67 inogen retention, membrane vesiculation, and procoagulant activity.

68 irculates as a procofactor with little or no procoagulant activity.

69 used a rapid and transient increase in liver procoagulant activity.

70 he addition of plasma restored much of their procoagulant activity.

71 ators that modify vascular function and have procoagulant activity.

72 ent and TF expression, indicative of reduced procoagulant activity.

73 oncentration, protein concentration, and BAL procoagulant activity.

74 ion, implicating TFPI in modulating platelet procoagulant activity.

75 HIT antibodies, with increased phospholipid procoagulant activity.

76 ng von Willebrand factor (VWF), reducing its procoagulant activity.

77 dense granules of activated platelets, is a procoagulant agent.

78 changes have been implicated in exposure of procoagulant aminophospholipids, we have now examined ca

79 rmation in the absence of Na(+) and that its procoagulant and anticoagulant activities are closely li

80 The balance between actions of procoagulant and anticoagulant factors protects organism

81 The specificity of thrombin for procoagulant and anticoagulant substrates is regulated a

82 sfunction and affect the equilibrium between procoagulant and anticoagulant systems, contributing to

83 portant in determining their ability to bind procoagulant and anticoagulant/fibrinolytic serine prote

84 Because factor XI displays both procoagulant and antifibrinolytic activities, it has bee

85 xpression led to a significant inhibition of procoagulant and antifibrinolytic pathways.

86 lfide exchange plays a role in regulating TF procoagulant and cell signaling functions.

87 e bacterial sepsis often leads to a systemic procoagulant and proinflammatory condition that can mani

88 R/PC-binding interactions not only result in procoagulant and proinflammatory effects, but also impac

89 is the protein substrate of the multifaceted procoagulant and proinflammatory enzyme, thrombin.

90 In addition to its procoagulant and proinflammatory functions mediated by c

91 namic process that leads to the formation of procoagulant and proinflammatory platelets under physiol

92 ctions between GGS and the contact system, a procoagulant and proinflammatory proteolytic cascade tha

93 Procoagulant and proinflammatory responses were assessed

94 concentrations, essential hypertension, and procoagulant and proinflammatory states, all of which in

95 ens can activate the endothelial cell into a procoagulant and proinflammatory surface, the two pathwa

96 of neutrophil extracellular traps (NETs), is procoagulant and prothrombotic.

97 cluster, we observed reduced TF expression, procoagulant and TF signaling activities (responses to f

98 gulation of pro-inflammatory, proliferative, procoagulant, and profibrotic genes; and at 4 weeks, the

99 ping novel antithrombotic agents that target procoagulant anionic polymers such as polyP with reduced

100 some cancer patients by profoundly disturbed procoagulant-anticoagulant balance, whereby warfarin fai

101 such as B. subtilis, can shift the delicate procoagulant-anticoagulant equilibrium toward thrombosis

102 sue ischemia, tips the natural anticoagulant/procoagulant balance of the endovascular wall to favor a

103 Unlike blebbing, procoagulant ballooning is irreversible and a consequenc

104 All MPs are procoagulant because they provide a membrane surface for

105 PG showed that FOG and PG both activate the procoagulant branch of the contact system.

106 t glomerulopathy and capillaropathy); (b) EC procoagulant changes: EC activation and disruption of th

107 cular coagulation, by reducing the number of procoagulant circulating microparticles and therefore de

108 Thrombin alone is a procoagulant, cleaving fibrinogen to make the fibrin clo

109 g with the 4-carboxyglutamic acid domains of procoagulant coagulation factors VII (FVII) and X (FX).

110 XIIIA, is essential for formation of highly procoagulant coated platelets following dual stimulation

111 platelets, consistent with the formation of procoagulant coated platelets.

112 Generation of active procoagulant cofactor factor Va (FVa) and its subsequent

113 reby creating a potent constitutively active procoagulant cofactor.

114 mutant lost its ability to interact with the procoagulant cofactors but not with the protective signa

115 PAR-1, but not for its interaction with the procoagulant cofactors.

116 e interaction of APC specifically with these procoagulant cofactors.

117 Activated factor VIII (FVIIIa) forms a procoagulant complex with factor IXa on negatively charg

118 itiated reactions with fresh reactants, that procoagulant complexes are produced during Tf-initiated

119 Moreover, FVIII-RH exhibits superior procoagulant effects compared with FVIII-BDD following a

120 t and endothelial cell activation as well as procoagulant effects of aPL directly on clotting pathway

121 up box 1 exerts powerful proinflammatory and procoagulant effects on WT PAEC, and appears to be an im

122 americ core histones reproduced any of these procoagulant effects.

123 orresponding proteome mixtures as sources of procoagulant end products and then varied the resupplyin

124 ave an elevated circulating concentration of procoagulant endothelial microparticles (MPs), leading t

125 We postulate that procoagulant events in the tissue microenvironment (nich

126 down-regulates LPS-mediated inflammatory and procoagulant expression by modulating actin organization

127 g disorders characterized by deficiencies in procoagulant factor VIII (FVIII) or factor IX (FIX), res

128 ted hydrolysis of a model protein substrate, procoagulant factor VIII, did not correlate with that of

129 The role of procoagulant factor X in a murine model of ovalbumin (OV

130 Because FIXa is an upstream procoagulant factor, impaired AT regulation of FIXa migh

131 Higher levels of procoagulant factors and factor XII deficiency may be ri

132 hysiologic consequences, explaining why many procoagulant factors are delivered both in the plasma an

133 vesicles, called microparticles, disseminate procoagulant factors from the brain into the systemic ci

134 gulates the clotting cascade by inactivating procoagulant factors Va and VIIIa by limited proteolysis

135 ned whether activated platelets and systemic procoagulant factors were associated with VTE in 32 olde

136 a modest increase in the activity of several procoagulant factors, but there was no difference in the

137 Among these procoagulant factors, only elevated factor XI was a risk

138 m integrity is associated with production of procoagulant factors, platelet aggregation, and facilita

139 and prolonged repletion of some but not all procoagulant factors.

140 B domain deleted (BDD) FVIII retains full procoagulant function and is expressed at higher levels

141 These antibodies block (inhibit) the procoagulant function of FVIII and thus are termed "inhi

142 Va is partially responsible for the enhanced procoagulant function of prothrombinase.

143 Furthermore, the BR inhibits procoagulant function of the variants, thereby restoring

144 TM-mediated regulation of tumor cell-driven procoagulant function strongly influences metastatic pot

145 B-domain sequences drives the expression of procoagulant function without the need for proteolytic p

146 ants require factor Va generated in situ for procoagulant function, and cofactor inactivation by the

147 t ThbdPro mice, which have elevated thrombin procoagulant function, gained more weight and developed

148 mune response to fVIII is independent of its procoagulant function, is both positively and negatively

149 surface PDI induces a marked increase in TF procoagulant function, whereas exogenous addition of PDI

150 latelet activation, aggregation, or platelet procoagulant function.

151 r cell-associated tissue factor and thrombin procoagulant function.

152 latelet phosphatidylserine (PS) exposure and procoagulant function.

153 eading to decreased platelet PS exposure and procoagulant function.

154 al to mFVIIa with respect to TF affinity and procoagulant functions.

155 r site for expression of proinflammatory and procoagulant genes during acute systemic inflammation.

156 may contribute to the toxic inflammatory and procoagulant host response to endotoxin.

157 bin complexes, and D-dimers were measured as procoagulant markers and markers of activation of coagul

158 ease, malignancy, genetic thrombophilia, and procoagulant markers) were adjusted for when comparing p

159 ions between leukocytes or leukocyte-derived procoagulant materials and the traditional hemostatic sy

160 Microbial polyphosphate, which is highly procoagulant, may function in host responses to pathogen

161 We identify a new procoagulant mechanism that contributes to thromboemboli

162 Despite a profound upregulation in procoagulant mechanisms, one-quarter of trauma patients

163 Leukocyte-released procoagulant mediators increase systemic thrombogenicity

164 ous studies showed that cultured ECs release procoagulant mediators into cell culture supernatants as

165 tin expression, microparticle formation, and procoagulant membrane changes, regardless of the activat

166 th procofactors in vivo in the presence of a procoagulant membrane surface during the early stages of

167 n unexpectedly important role in providing a procoagulant membrane surface in vivo.

168 PI and its cofactor, protein Z (PZ), inhibit procoagulant membrane-bound factor Xa by the branched pa

169 ctivity relative to FVIIa upon exposure to a procoagulant membrane.

170 in a manner uniquely dependent on protein Z, procoagulant membranes, and pH.

171 on of extracellular thiol pathway-dependent, procoagulant microparticles (MPs).

172 Procoagulant microparticles from endothelial cells and l

173 ote thrombosis is by inducing the release of procoagulant microparticles from endothelial cells.

174 or instance, tumor cells release TF-positive procoagulant microparticles into the circulation and the

175 itization of platelets and the generation of procoagulant microparticles that may express sustained h

176 dothelial- and leukocyte-derived circulating procoagulant microparticles were isolated and quantified

177 venous thrombosis, and (2) cancer promotes a procoagulant milieu, we hypothesize that Gas6 may be inv

178 The proinflammatory and procoagulant molecule C-reactive protein (CRP), which in

179 In this study, we analyzed the role of the procoagulant molecule tissue factor (TF) in a mouse mode

180 issue factor and release proinflammatory and procoagulant molecules such as granular enzymes, cytokin

181 was required for the final release of highly procoagulant MPs from filopodia.

182 mmarize our current knowledge of the role of procoagulant MPs in hemostasis and thrombosis.

183 zed that patients with ALF develop increased procoagulant MPs in proportion to the severity of system

184 Highly procoagulant MPs of specific size ranges are associated

185 ough tissue factor upregulation, shedding of procoagulant MPs, endothelial nitric oxide synthase down

186 as associated with a progressive shedding of procoagulant MPs.

187 c activity in vivo attenuated the release of procoagulant MPs.

188 ely onto phosphatidylserine-positive, highly procoagulant MPs.

189 s patients have higher levels of circulating procoagulant MVs than healthy controls.

190 ovide a biochemical rationale for the strong procoagulant nature of venom prothrombinase.

191 ges affecting platelet numbers and function, procoagulant or anticoagulant factors, fibrinolysis, and

192 r and tissue factor pathway inhibitor toward procoagulant phenotype in human coronary artery endothel

193 e fibrin structure and stability reflect the procoagulant phenotype of the endogenous cells, and sugg

194 w that histone-activated platelets possess a procoagulant phenotype that drives plasma thrombin gener

195 he switch of these cells from a resting to a procoagulant phenotype.

196 eceptor (PAR)1 and PAR4 in the generation of procoagulant phenotypes on platelet membranes.

197 activation is associated with the release of procoagulant phosphatidylserine-rich small membrane vesi

198 zymatic generation and active provision of a procoagulant phospholipid surface enriched in 12/15-lipo

199 o fibrin displayed shape change, exposure of procoagulant phospholipids, and the formation of small c

200 oducts can help deliver appropriate doses of procoagulant plasma and platelets quicker and more safel

201 Targeting polyphosphate abolishes procoagulant platelet activity in a factor XII-dependent

202 We therefore propose the term procoagulant platelet as the unifying terminology.

203 in alphaIIbbeta3 and the physiologic role of procoagulant platelet formation in the regulation of pla

204 The identity of the procoagulant platelet has been elusive.

205 When platelets are strongly stimulated, a procoagulant platelet subpopulation is formed that is ch

206 stigate the mechanisms responsible for these procoagulant platelet-associated changes in integrin alp

207 Procoagulant, platelet, erythrocyte, and endothelial but

208 Procoagulant, platelet, erythrocyte, and endothelial mic

209 ly and markedly enhances the ability to form procoagulant platelets and increases platelet-dependent

210 major coagulation factors on the surface of procoagulant platelets and suggest its importance in pro

211 e perspectives on the biomarker potential of procoagulant platelets for thrombotic events as well as

212 ceiving aspirin therapy indicates that these procoagulant platelets form despite aspirin therapy, but

213 Procoagulant platelets formed upon strong platelet stimu

214 , and thrombin; (3) significant increases of procoagulant platelets induced by convulxin/thrombin and

215 e we show that alphaIIbbeta3 inactivation in procoagulant platelets relies on a sustained high intrac

216 blood coagulation factors on the surface of procoagulant platelets was investigated using confocal m

217 ion, which is essential for the formation of procoagulant platelets, is impaired in the absence of cy

218 mPTP-dependent alkalinization occurred in procoagulant platelets, suggesting a possible alternativ

219 anism for enhancement of calpain activity in procoagulant platelets.

220 to the switch mechanisms from aggregating to procoagulant platelets.

221 Polyphosphate is an inorganic procoagulant polymer.

222 The greater procoagulant potential is related to more efficient FV r

223 we assessed the influence of histones on the procoagulant potential of human platelets in platelet-ri

224 summary, our results provide evidence of the procoagulant potential of smaller and larger endothelial

225 and requires activation to fully exhibit the procoagulant potential.

226 nal microparticles at the levels that have a procoagulant potential.

227 from apoptotic platelets and correlates with procoagulant potential.

228 ges, tamponades, tourniquets, dressings, and procoagulant powders.

229 and induce an intracellular signaling and a procoagulant/proinflammatory phenotype that leads to thr

230 ociated initiator of coagulation and related procoagulant properties in the blood.

231 nication destroyed complement-activating and procoagulant properties in vitro and rendered the DVs bi

232 Red blood cells (RBCs) demonstrate procoagulant properties in vitro, and elevated hematocri

233 ions affects the proinflammatory but not the procoagulant properties of fibrinogen, targeting the gam

234 eleased vesicles displays the most prominent procoagulant properties.

235 ted with factor FX (FX)-S195A, but not other procoagulant protease zymogens, also results in initiati

236 The sTF-annexin V chimera is a targeted procoagulant protein that may be useful in accelerating

237 The procoagulant protein tissue factor (F3) is a powerful gr

238 asma and that this induces expression of the procoagulant protein tissue factor (TF) in monocytes.

239 articularly phosphatidylserine (PS), and the procoagulant protein tissue factor (TF), which is the ma

240 leukocytes induces expression of the potent procoagulant protein tissue factor that triggers thrombo

241 nd reducing the pathologic expression of the procoagulant protein tissue factor.

242 s encoding proinflammatory cytokines and the procoagulant protein, tissue factor.

243 enetic loci associated with plasma levels of procoagulant proteins and risk of thrombotic disease.

244 pathways by which platelets and circulating procoagulant proteins synergistically orchestrate VTE re

245 r the combinatorial assembly of adhesive and procoagulant proteins to study thrombosis as well as to

246 lebrand factor as well as other adhesive and procoagulant proteins), and FcgammaR(-/-) (lacking funct

247 for the cleavage of substrates mediating its procoagulant, prothrombotic, and signaling functions.

248 ing that Orai1 is crucial for the platelets' procoagulant response rather than for other Ca(2+)-depen

249 inical factors that trigger or intensify the procoagulant response to sepsis is warranted.

250 straints intended to restrict an unregulated procoagulant response.

251 ting pool of blood TF to sustain an adequate procoagulant response.

252 LPS-induced TF expression in macrophages and procoagulant responses in endotoxemia.

253 ctivation by bacterial omptins to potentiate procoagulant responses to bacterial infection.

254 and rheological factors contribute to focal procoagulant responses to E. coli.

255 isplay sustained inflammatory, vascular, and procoagulant responses.

256 the thrombin/thrombomodulin complex, plays a procoagulant role during fibrin clot formation.

257 A subpopulation of platelets fulfills a procoagulant role in hemostasis and thrombosis by enabli

258 Our results demonstrate an unexpected procoagulant role of the protein C pathway that may have

259 Several hemostatic factors showed a procoagulant shift with decreasing kidney function in co

260 nd reduced platelet activation/expression of procoagulant signaling.

261 Ballooning and procoagulant spreading of platelets are driven by fluid

262 , Cl(-), or water entry impaired ballooning, procoagulant spreading, and microparticle generation, an

263 ontact surfaces, by a process that we termed procoagulant spreading.

264 Plaque complications may require a procoagulant state and an increased protease activity, l

265 ction with AT, and thereby contribute to the procoagulant state associated with P falciparum infectio

266 Septic shock is a highly inflammatory and procoagulant state associated with significant mortality

267 t is recognized that leukocytes may induce a procoagulant state at sites of inflammation, the critica

268 microvasculature assumes an inflammatory and procoagulant state in a variety of different diseases, i

269 protein C system promotes a proinflammatory, procoagulant state in brain microvessels.

270 Although TF has been clearly linked to a procoagulant state in obesity, emerging genetic and phar

271 Asthma is associated with a procoagulant state in the bronchoalveolar space, further

272 r a regulatory protein deficiency, sets up a procoagulant state in these diseases as well as in the a

273 ositive patients (p=0.04), suggesting a more procoagulant state in this early symptomatic subgroup.

274 We analyzed the native procoagulant state of LT recipients, identified through

275 sms by which hypercholesterolemia produces a procoagulant state remain undefined.

276 modulates the dysregulated proinflammatory, procoagulant state that leads to lung injury.

277 o inhibit the change in the endothelium to a procoagulant state that takes place in the pig organ aft

278 d to microangiopathic hemolytic anemia and a procoagulant state with or without damage to the kidneys

279 y response syndrome (SIRS) associated with a procoagulant state.

280 esis by damaging endothelium and promoting a procoagulant state.

281 ciparum infection is often associated with a procoagulant state.

282 ired by the hemostasis system because of its procoagulant state.

283 charide infusion attenuates proinflammatory, procoagulant states that induce lung vascular injury in

284 y a role for TFPI in dampening intravascular procoagulant stimuli that lead to thrombin generation, e

285 n and activate less protein C in response to procoagulant stimuli.

286 coupled to provide a sustained, disseminated procoagulant stimulus for use as a biologic toxin.

287 thromboelastometry EVs exerted a significant procoagulant stimulus, which could be partly reversed by

288 The results suggest that the distinctive procoagulant substrate specificity of MzT, in activating

289 amatically reduced catalytic efficiency with procoagulant substrates while largely preserving thrombo

290 These platelets form a procoagulant surface, supporting fibrin formation, and r

291 Tissue factor (TF) is a procoagulant that plays an important part in tumor angio

292 The procoagulant tissue factor (TF) is thought to play a rol

293 eregulation of vascular effectors, including procoagulant tissue factor (TF), this study explores whe

294 Given that thrombin induces procoagulant tissue factor (TF), we examined how TF acti

295 iven thrombosis in fetal loss, expression of procoagulant tissue factor was significantly increased i

296 to increased C3 deposition, C5a release, and procoagulant tissue-factor expression.

297 oduce an array of toxic compounds, including procoagulants to defend themselves and incapacitate prey

298 lected pathogens appear to benefit from host procoagulants to drive bacterial virulence.

299 tor Xa might prove useful as new therapeutic procoagulants to treat deficiencies upstream of the comm

300 od vessel injury by the acute release of the procoagulant von Willebrand factor, which is stored in u